MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

AstraZeneca PLC ADR

Gesloten

72.26 -0.37

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

72.03

Max

72.8

Belangrijke statistieken

By Trading Economics

Inkomsten

-162M

1.7B

Verkoop

1.3B

15B

K/W

Sectorgemiddelde

32.667

63.778

EPS

1.045

Dividendrendement

2.11

Winstmarge

11.188

Werknemers

94,300

EBITDA

330M

4.4B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+28.35% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

2.11%

2.39%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

228B

Vorige openingsprijs

72.63

Vorige sluitingsprijs

72.26

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

AstraZeneca PLC ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 mrt 2025, 03:15 UTC

Belangrijke Marktbewegers

Harbour BioMed Shares Soar on News of AstraZeneca Collaboration

17 mrt 2025, 07:42 UTC

Acquisities, Fusies, Overnames

AstraZeneca Buys Belgian EsoBiotec for Up to $1 Billion to Boost Cell-Therapy Portfolio

6 feb 2025, 11:07 UTC

Winsten

AstraZeneca Expects Revenue, Earnings Growth Despite Sales Drop in China -- Update

31 mrt 2025, 09:31 UTC

Populaire aandelen

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

17 mrt 2025, 14:43 UTC

Marktinformatie

AstraZeneca's Latest Rare-Disease Drug Results Slightly Disappoint, Barclays Says -- Market Talk

17 mrt 2025, 13:55 UTC

Marktinformatie
Acquisities, Fusies, Overnames

AstraZeneca's EsoBiotec Deal Seen as Logical -- Market Talk

17 mrt 2025, 07:04 UTC

Acquisities, Fusies, Overnames

AstraZeneca: Transaction Doesn't Affect Fincl Guidance for 2025.

17 mrt 2025, 07:03 UTC

Acquisities, Fusies, Overnames

AstraZeneca: Acquisition Expected to Close in 2Q 2025

17 mrt 2025, 07:03 UTC

Acquisities, Fusies, Overnames

AstraZeneca to Pay Up to $575M Upon Development, Regulatory Milestones Being Met

17 mrt 2025, 07:01 UTC

Acquisities, Fusies, Overnames

AstraZeneca to Make Initial Payment of $425M on Deal Closing

17 mrt 2025, 07:01 UTC

Acquisities, Fusies, Overnames

AstraZeneca Buying EsoBiotec for up to $1B

17 mrt 2025, 07:01 UTC

Acquisities, Fusies, Overnames

AstraZeneca to Buy EsoBiotec to Advance Cell Therapy Ambition

17 mrt 2025, 07:00 UTC

Acquisities, Fusies, Overnames

AstraZeneca to Buy EsoBiotec

28 feb 2025, 12:00 UTC

Top Nieuws

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

26 feb 2025, 14:59 UTC

Marktinformatie

AstraZeneca's Breast-Cancer Drug Results Seen as Positive Surprise -- Market Talk

26 feb 2025, 08:04 UTC

Marktinformatie
Winsten

AstraZeneca's Cancer Drug Pipeline Could Fuel $80 Billion Sales Target -- Market Talk

20 feb 2025, 11:34 UTC

Acquisities, Fusies, Overnames

FibroGen: Co. Maintains Its Rights to Roxadustat in U.S. and in All Markets Not Licensed to Astellas >FGEN

20 feb 2025, 11:34 UTC

Acquisities, Fusies, Overnames

FibroGen: Upon Closing, AstraZeneca Will Obtain All Rights to Roxadustat in China >FGEN

20 feb 2025, 11:33 UTC

Acquisities, Fusies, Overnames

FibroGen: Following Close of Transaction, Co. Will Repay Term Loan Facility to Investment Funds Managed by Morgan Stanley Tactical Value >FGEN

20 feb 2025, 11:33 UTC

Acquisities, Fusies, Overnames

FibroGen; Will Receive Enterprise Value of $85M Plus FibroGen Net Cash Held in China at Closing, Currently Estimated to Be About $75M >FGEN

20 feb 2025, 11:31 UTC

Acquisities, Fusies, Overnames

FibroGen: To Continue to Advance Its Oncology Pipeline, With Initiation of Phase 2 Monotherapy Trial of FG-3246 in Metastatic Castration-Resistant Prostate Cancer in 2Q 2025 >FGEN

20 feb 2025, 11:30 UTC

Acquisities, Fusies, Overnames

FibroGen Announces Sale of FibroGen China to AstraZeneca for About $160M

13 feb 2025, 10:49 UTC

Marktinformatie
Winsten

AstraZeneca Stands Out With Catalyst-Rich, Diversified Pipeline -- Market Talk

7 feb 2025, 10:30 UTC

Top Nieuws

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

6 feb 2025, 15:18 UTC

Marktinformatie

U.K. Health System Needs to Improve Investment Environment, AstraZeneca CEO Says -- Market Talk

6 feb 2025, 13:24 UTC

Marktinformatie

AstraZeneca's Increased R&D Spend Is a Positive -- Market Talk

6 feb 2025, 12:01 UTC

Winsten

Global Stocks in Spotlight: BYD, Kering, Maersk -- WSJ

6 feb 2025, 11:22 UTC

Marktinformatie
Winsten

AstraZeneca's Sales Beat, Pipeline Outshines Margin Miss -- Market Talk

6 feb 2025, 11:18 UTC

Marktinformatie
Winsten

AstraZeneca's Outlook Makes Midterm Target Look Achievable -- Market Talk

6 feb 2025, 11:02 UTC

Marktinformatie
Winsten

AstraZeneca's China Woes Seem Manageable -- Market Talk

Peer Vergelijking

Prijswijziging

AstraZeneca PLC ADR Prognose

Koersdoel

By TipRanks

28.35% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 93.18 USD  28.35%

Hoogste 98 USD

Laagste 88 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor AstraZeneca PLC ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Technische score

By Trading Central

72.18 / 73.68Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over AstraZeneca PLC ADR

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.